BioInsights - Advancing genome edited allogeneic cell therapies into the clinic

Advancing genome edited allogeneic cell therapies into the clinic

Cell & Gene Therapy Insights 2022; 8(7), 817–823

DOI: 10.18609/cgti.2022.126

Published: 25 August 2022
Steve Kanner

Steve Kanner is the CSO at Caribou Biosciences responsible for the company’s therapeutic discovery, research, and development activities. Before joining Caribou in 2017, Steve was Vice President, Head of Biology, at Arrowhead Pharmaceuticals, leading a department in discovery of RNAi therapeutics for oncology, genetic diseases, and other indications. Prior to Arrowhead Pharmaceuticals, he served in various positions of increasing responsibility in both oncology and inflammation drug discovery at Bristol-Myers Squibb, Agensys/Astellas, and Astex Pharmaceuticals. Steve has authored over 85 publications in both peer-reviewed journals and books, and he is an inventor on numerous U.S. and foreign patents and patent applications. Steve received his undergraduate degree in Genetics from the University of California, Berkeley and his PhD in Immunology and Microbiology from the University of Miami’s Miller School of Medicine. His post-doctoral fellowship was funded by the National Institutes of Health and was conducted at the University of Virginia.